Pfizer’s Not Waiting To Exhale; Firm Takes Action By Terminating Exubera
This article was originally published in The Pink Sheet Daily
Executive Summary
After the inhaled insulin failed to gain traction, Pfizer also has decided to stop funding investment in a second generation device.